ADx Neurosciences, operated by CEO Koen Dewaele, and CSO Eugeen Vanmechelan, creates tailor-made antibodies and assays to quantify unique biomarkers in a wide variety of neurodegenerative diseases and conditions such as Alzheimer’s disease, Parkinson’s disease and traumatic brain injury. Their assays enable early detection before symptoms appear, providing valuable information from the drug development phase up to clinical practice, to improve the life of patients. ADx is working on biomarkers for amyloid beta and tau, synuclein, which can be used in therapeutics development & trials.